French-based UroMems has raised a record $47 million (€44 million) in a Series C financing round to fund pivotal clinical trials of its innovative UroActive™ System. The round was led by Credit Mutuel Innovation and saw participation from the European Innovation Council and existing investors such as Wellington Partners, Bpifrance, Supernova Invest, Hil-Invent, b-to-v Partners, and Financière Arbevel. The UroActive™ System, the first smart automated implant to treat Stress Urinary Incontinence (SUI), has shown promising results in initial clinical trials, with substantial improvements in patient outcomes and quality of life without any need for revision or explants over a year. This development underscores the potential for the UroActive™ System to become the new standard of care for SUI, a condition that affects millions globally.

Healthcare Technology, Investment,France, Europe, United States